DRI Healthcare AI Stock Analysis
Want to see TSE:DHT.UN full AI Analyst Report?
DRI Healthcare (DHT.UN) AI Stock Analysis
DRI Healthcare
(TSX:DHT.UN)
The score is held back primarily by weaker financial quality (volatile net income, higher leverage, and persistently negative/free cash flow). Offsetting this are constructive price momentum and a notably positive earnings call with above-guidance EBITDA tracking and improved long-term outlook, while valuation is mixed due to the negative P/E despite a moderate dividend yield.
DRI Healthcare (DHT.UN) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 734.05M
- Dividend Yield
- 3.09%
- Average Volume (3M)
- 39.63K
- Price to Earnings (P/E)
- 12.4
- Beta (1Y)
- 0.24
- Revenue Growth
- 3.03%
- EPS Growth
- ―
- Country
- Canada
- Employees
- 32
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Asset Management
DRI Healthcare Business Overview & Revenue Model
Company Description
DRI Healthcare Trust is an unincorporated open-ended company. It engages in the provision of differentiated exposure to the fast-growing pharmaceutical and biotechnology industries through ownership and acquisition of royalties on pharmaceutical prod...
How the Company Makes Money
DRI Healthcare makes money primarily by purchasing (or otherwise acquiring) economic rights to future cash flows associated with pharmaceutical products and then collecting those cash flows over time. Key revenue streams typically include: (1) Produc...
DRI Healthcare Earnings Call Summary
The call was strongly positive overall. Management reported year-to-date growth above the high end of expectations, a 9% increase in third-quarter normalized cash receipts and adjusted EBITDA, successful Ekterly monetization and Juvmo deployment, expanded capital capacity, a larger pipeline and higher long-term growth aspirations. The principal challenges were Zejula's sharp decline and impairment, expected future Orserdu declines, quarterly margin and earnings-per-unit pressure, and a slower initial Juvmo ramp; however, management stated that several of these items were anticipated in its underwriting.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
DRI said it is tracking above the high end of its 2026 adjusted EBITDA guidance of $157 million to $162 million with no further transactions assumed this year, expects quarterly credit facility interest expense of approximately $4.3 million in the fourth quarter, and continues to target EBITDA margins in the high 80s to 90% range in any given quarter and around that high 80s to low 90s level within a year and over multiple years. Capital deployment over 2026 to 2030 is now expected to come in above the prior aspirational deployment range of $800 million to $1 billion, while Juvmo on its own allows DRI to hit or exceed its previously announced adjusted EBITDA aspirations through 2030 and its adjusted EBITDA CAGR aspirations for the same period to meaningfully exceed the prior ranges communicated. Product guidance included approximately $19 million of Orserdu royalties in Q4 '26, with 2027 onwards likely to see declines; flat Omidria sales for the next few years; approximately $4.8 million of Spinraza royalties in Q4 '26 versus the roughly $3.7 million guided to in August; Roche’s approximately 20% growth guidance for 2026 and flat revenue guidance in 2027 for Xolair, translating to approximately $2.6 million of royalty receipts in Q1 '27; next Xenpozyme receipts expected in Q4 '26; Juvmo’s first royalty receipt expected in the first quarter of 2027 and 4 fixed annual payments totaling $93.75 million, the first due in September 2027; and elegrobart remaining on track for a Q1 2027 BLA submission.
DRI Healthcare Financial Statement Overview
Summary
Mid-to-weak fundamentals overall: revenue growth and strong TTM operating profitability/cash receipts are positives, but earnings have been volatile, leverage has risen (debt ~1.0x equity), and free cash flow is consistently negative with a sharply worse TTM shortfall, increasing financing risk.
Income Statement
56NeutralBalance Sheet
52NeutralCash Flow
41Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 203.70M | 195.17M | 138.55M | 117.44M | 79.87M | 73.33M |
| Gross Profit | 84.54M | -21.51M | 66.60M | -20.36M | 79.87M | 73.33M |
| EBITDA | 189.52M | 92.25M | 147.35M | 105.59M | 76.77M | 66.06M |
| Net Income | 60.46M | -51.35M | -3.36M | 91.50M | 11.60M | 21.56M |
Balance Sheet | ||||||
| Total Assets | 1.13B | 941.10M | 984.87M | 833.16M | 633.42M | 436.69M |
| Cash, Cash Equivalents and Short-Term Investments | 41.06M | 42.35M | 36.50M | 62.84M | 36.69M | 61.71M |
| Total Debt | 611.60M | 482.06M | 432.12M | 145.48M | 244.99M | 43.92M |
| Total Liabilities | 652.98M | 503.32M | 457.34M | 273.46M | 261.08M | 57.71M |
| Stockholders Equity | 473.87M | 437.78M | 527.53M | 561.50M | 372.34M | 378.99M |
Cash Flow | ||||||
| Free Cash Flow | -299.76M | -11.42M | -129.84M | -313.90M | -197.03M | -232.46M |
| Operating Cash Flow | 153.68M | 78.11M | 155.41M | 76.38M | 77.47M | 91.86M |
| Investing Cash Flow | -266.95M | -81.64M | -293.31M | -128.81M | -273.67M | -372.33M |
| Financing Cash Flow | 118.71M | 9.56M | 111.56M | 78.57M | 171.17M | 342.18M |
DRI Healthcare Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DHT.UN, the sentiment is Positive. The current price of 19.52 is above the 20-day moving average (MA) of 18.56, above the 50-day MA of 18.05, and above the 200-day MA of 17.17, indicating a bullish trend. The MACD of 0.35 indicates Negative momentum. The RSI at 73.81 is Negative, neither overbought nor oversold. The STOCH value of 84.51 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:DHT.UN.
DRI Healthcare Peers Comparison
Overall Rating
TSE:GTII69Neutral- TSE:DHT.UN58Neutral
TSE:CURA52Neutral
TSE:VRNO51Neutral
TSE:CL45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:GTII | 69Neutral | CAD 2.05B | 15.49 | 5.30% | ― | 6.44% | 127.50% |
| TSE:DHT.UN | 58Neutral | CAD 1.07B | 12.41 | 13.57% | 3.09% | 3.03% | ― |
| TSE:CURA | 52Neutral | CAD 3.37B | -245.71 | -1.47% | ― | 5.01% | 92.12% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:VRNO | 51Neutral | CAD 2.17B | -1.56 | -30.11% | ― | 0.61% | 37.92% |
| TSE:CL | 45Neutral | CAD 351.50M | -1.72 | -28.27% | ― | -2.43% | -80.34% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:DHT.UN | Dri Healthcare Plc Trust | 19.52 | 4.69 | 31.66% | |
| TSE:CURA | Curaleaf Holdings (Otc) | 12.69 | 1.86 | 17.17% | |
| TSE:GTII | Green Thumb Industries (OTC) | 9.37 | 0.08 | 0.86% | |
| TSE:CL | Cresco Labs OTC | 0.77 | -0.73 | -48.67% | |
| TSE:VRNO | Verano Holdings Corp. | 6.32 | 0.00 | 0.00% |
DRI Healthcare Corporate Events
DRI Healthcare Schedules Q3 2026 Results Release and Investor Call
PositiveDRI Healthcare Trust will release its third quarter 2026 financial results after markets close on November 4, 2026, and will host a conference call and live webcast the following morning at 8:00 a.m. ET to review performance. The event will include p...
DRI Healthcare Buys Parkinson’s Drug Royalties After FDA Clears Juvmo
PositiveDRI Healthcare Trust is deepening its exposure to neurology royalties after the U.S. FDA approved Juvmo, a once-daily oral dopamine D1/D5 partial agonist for treating motor symptoms of Parkinson’s disease. The trust has built a diversified portfolio...
DRI Healthcare to Spend US$316 Million on Tavapadon Parkinson’s Royalty Deal
PositiveDRI Healthcare Trust has agreed to acquire royalty participation rights in U.S. net sales of tavapadon from Bain Capital and NovaQuest for a purchase price of US$316 million, payable upon U.S. FDA approval. Tavapadon is a once-daily, oral, selective...
DRI Healthcare Posts Record Q1 Income and Bolsters Balance Sheet With New Funding
PositiveDRI Healthcare Trust reported record first-quarter total income of $50.6 million for 2026, supported by total cash receipts of $58.4 million and adjusted EBITDA of $52.8 million with a 90% margin. Despite modest net earnings of $0.5 million and conti...
DRI Healthcare Realizes US$178 Million from EKTERLY Royalty Exit
PositiveDRI Healthcare Trust has received approximately US$178 million from the exercise of its contractual put option on its royalty participation right in EKTERLY, triggered by Chiesi Group’s acquisition of KalVista Pharmaceuticals, Inc., bringing the tran...
DRI Healthcare Posts Record Q2 Results, Executes Ekterly Put and Adds Biopharma Experts to Board
PositiveDRI Healthcare reported record second-quarter 2026 results, with total income of $50.1 million, total cash receipts of $46.5 million and adjusted EBITDA of $42.6 million, reflecting a 92% adjusted EBITDA margin. The trust also repurchased units under...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026